Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 2/20 | 0.40 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 4/20 | 0.38 |
| ▸ | RXRB | P28702 | 4/20 | 0.38 |
| ▸ | RXRG | P48443 | 3/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308100 | 0.89 | CES2 (0.42) | CES2NOTUMRXRARXRBRXRG | |
| SCHEMBL6909178 | 0.86 | CES2 (0.40) | POLQCES2NOTUMRXRARXRB | |
| SCHEMBL3024423 | 0.85 | CES2 (0.39) | POLQGPR17CES2NOTUMMRGPRX4 | |
| SCHEMBL2313613 | 0.84 | KDM4E (0.45) | CES2NOTUMRXRARXRBRXRG | |
| SCHEMBL3369693 | 0.83 | CES2 (0.48) | GPR17CES2NOTUMSRD5A2RXRA | |
| SCHEMBL27703953 | 0.81 | POLQ (0.41) | POLQNOTUMMRGPRX4SIGMAR1ALDH1A1 | |
| SCHEMBL420887 | 0.80 | RXRA (0.46) | GPR17CES2NOTUMRXRARXRB | |
| SCHEMBL420868 | 0.79 | CETP (0.44) | NOTUMRXRARXRBRXRGALDH1A1 | |
| SCHEMBL423246 | 0.77 | CES2 (0.43) | GPR17CES2SRD5A2RXRARXRB | |
| SCHEMBL30532294 | 0.77 | CES2 (0.43) | GPR17CES2SRD5A2RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| EP-2391603-B1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8404673-B2 | Carbocyclic GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404673-B2 | Carbocyclic GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010020548-A1 | GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020548-A1 | GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | GLRA1, GLRA2, GRIA1 | POLQ 4849/4885GPR17 335/4885CES2 1596/4885 |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | POLQ 2311/4885GPR17 2074/4885CES2 1184/4885 |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | POLQ 2311/4885GPR17 2074/4885CES2 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.